Holen Sie sich die Stockscreener-App
11.83
2.35%
-0.285
Handel nachbörslich:
11.77
-0.06
-0.51%
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Fed Meeting: Does Amneal Pharmaceuticals Inc stock have upside surprise potential2026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 5.5%Here's What Happened - MarketBeat
Amneal Pharmaceuticals Inc (AMRX) Shares Gap Down to $12.73 on M - GuruFocus
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment - Yahoo Finance
What Amneal Pharmaceuticals (AMRX)'s Return to Profitability and 2026 Guidance Means For Shareholders - Sahm
Amneal Pharmaceuticals Conference: “Amneal 2.0” Targets 2026 Growth in Biosimilars, CREXONT and AvKARE Shift - MarketBeat
Amneal (AMRX) Stock Analysis 2026: Strong Gains vs. Future Growth ConcernsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Shorts Report: Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdForecast Cut & Weekly Stock Breakout Alerts - baoquankhu1.vn
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead - Finviz
AMRX: Biosimilars and specialty launches fuel growth, with profitability and global expansion accelerating - TradingView
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Best Value Stocks to Buy for March 9th - The Globe and Mail
Trade Report: Will Amneal Pharmaceuticals Inc benefit from current market trends2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
Citigroup Inc. Purchases 101,166 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by Quantbot Technologies LP - MarketBeat
Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Amneal to Participate in Upcoming Investor Conference - National Today
Amneal (AMRX) Co-CEO Chintu Patel gets major RSU and PSU grants - Stock Titan
Amneal (AMRX) Co-CEO awarded time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) EVP awarded time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) CFO granted time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) grants RSU and performance stock awards to EVP - Stock Titan
Amneal (NYSE: AMRX) EVP Andrew Boyer granted time- and performance-based RSUs - Stock Titan
AMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Vanguard Group Inc. - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Exploring A 19% Upside Potential - DirectorsTalk Interviews
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Drops By 16.4% - MarketBeat
Truist raises Amneal Pharmaceuticals stock price target on margin focus By Investing.com - Investing.com Canada
Truist raises Amneal Pharmaceuticals stock price target on margin focus - Investing.com
Truist Adjusts Price Target on Amneal Pharmaceuticals to $17 From $15, Maintains Buy Rating - marketscreener.com
Truist Financial Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price - MarketBeat
Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments - Sahm
Earnings Miss: Can Amneal Pharmaceuticals Inc be the next market leaderQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Envestnet Asset Management Inc. Takes $1.61 Million Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative - Sahm
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release - simplywall.st
Earnings call transcript: Amneal Pharmaceuticals beats expectations in Q4 2025 - Investing.com Australia
Why Amneal (AMRX) Stock Is Trading Lower Today - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2026 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals (NASDAQ: AMRX) grows biosimilars, Parkinson’s and injectables - Stock Titan
Amneal (AMRX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Amneal Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Amneal Q4 2025 slides: specialty surge drives 11% revenue growth - Investing.com
Amneal Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:AMRX) 2026-02-27 - Seeking Alpha
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million - Benzinga
Amneal Posts Strong Q4 Results and Raises 2026 Outlook - TipRanks
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for 2026 - marketscreener.com
Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations - Finviz
Amneal Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates - Yahoo Finance
Amneal Pharmaceuticals : Fourth Quarter 2025 Earnings Presentation - marketscreener.com
Amneal Pharmaceuticals beats Q4 estimates, guides below views - Investing.com
AMNEAL PHARMACEUTICALS ($AMRX) Releases Q4 2025 Earnings - Quiver Quantitative
Amneal (NASDAQ: AMRX) returns to profit and guides 2026 growth - Stock Titan
(AMRX) Amneal Pharmaceuticals Expects 2026 Revenue Range $3.05B to $3.15B, vs. FactSet Est of $3.21B - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q4 Revenue $814.3M, vs. FactSet Est of $807.4M - marketscreener.com
(AMRX) Amneal Pharmaceuticals Expects 2026 Adjusted EPS Range $0.93 to $1.03, vs. FactSet Est of $0.94 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $0.21 per Share, vs. FactSet Est of $0.18 - marketscreener.com
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):